Loading…
NanH and PknG putative virulence factors as a recombinant subunit immunogen against Corynebacterium pseudotuberculosis infection in mice
•Mice immunized with rNanH+saponin (G2) exhibited a survival rate of 60%.•Mice immunized with rPknG+saponin (G3) exhibited a survival rate of 20%.•G2 showed the best protection against Corynebacterium pseudotuberculosis challenge.•rNanH induced significant production of IgG2a antibodies.•rNanH induc...
Saved in:
Published in: | Vaccine 2020-12, Vol.38 (51), p.8099-8106 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Mice immunized with rNanH+saponin (G2) exhibited a survival rate of 60%.•Mice immunized with rPknG+saponin (G3) exhibited a survival rate of 20%.•G2 showed the best protection against Corynebacterium pseudotuberculosis challenge.•rNanH induced significant production of IgG2a antibodies.•rNanH induced significant production of cytokines related to a Th1 immune response.
Despite the economic and zoonotic relevance of caseous lymphadenitis, a competent immunoprophylaxis tool is still necessary. Here, we evaluated two putative virulence factors of Corynebacterium pseudotuberculosis, rNanH, and rPknG, as recombinant subunit vaccines in a murine model against the infection by C. pseudotuberculosis. Three groups of ten Balb/c mice each were inoculated with a sterile 0.9% saline solution (G1), rNanH (G2), or rPknG (G3) in formulations containing saponin as an adjuvant. The mice received two vaccine doses intercalated by a 21-day interval and were challenged with 2 × 104 CFU/mL of the C. pseudotuberculosis MIC–6 strain 21 days after the last immunization. The total IgG, IgG1, and IgG2a production levels increased significantly in the experimental groups (G2 and G3) on day 42. The highest levels of IgG2a antibodies in G2 and G3 were observed compared to IgG1 levels. G3 showed a significant (p |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2020.11.010 |